TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27919965
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with docetaxel (10 mg/kg bevacizumab i.v. plus 50 mg/m2 docetaxel i.v.)
Study: 27919965
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with paclitaxel (10 mg/kg bevacizumab i.v. plus 90 mg/m2 paclitaxel i.v.)
Study: 27919965
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg i.v.) alone after progression
Study: 24838177
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily for 5 days (Period 1)
Study: 24838177
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily coadministered with telaprevir 750 mg every 8 h for 10 days (Period 2)
Study: 19996954
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of bupivacaine mixed with contrast
Study: 19996954
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml of bupivacaine mixed with contrast
Study: 17511185
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg sufentanil and 2.5 mg bupivacaine
Study: 17511185
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tramadol and 2.5 mg bupivacaine
Study: 15895421
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS, 15 Hz, 110% above motor threshold, 10 daily sessions)
Study: 1355797
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zinc daily
Study: 30025953
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment with NSAIDs and biologics
Study: 26989846
Drug: Telmisartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine combination tablets (bedtime administration)
Study: 26989846
Drug: Telmisartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine combination tablets (morning administration)
Study: 26989846
Drug: Telmisartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine combination tablets (both timings)
Study: 12073203
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits with reduced systemic heparinization
Study: 12073203
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits with full systemic heparinization
Study: 8011007
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation (Primperan)
Study: 2679289
Drug: Antiplatelet or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet or anticoagulant therapy, early initiation
Study: 766619
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g hydrocortisone hemisuccinate
Study: 766619
Drug: 0.50 g
Normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g hydrocortisone hemisuccinate
Study: 766619
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g hydrocortisone hemisuccinate
Study: 7312235
Drug: Conventional paracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional paracervical block (almost simultaneous injection of the 2 sides)
Study: 7312235
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block with a 10-minute interval between injections
Study: 29794277
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (LDK) 1 mg/kg
Study: 29794277
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (MOR) 0.1 mg/kg
Study: 18240258
Drug: Anti-TNFα treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα treatment in PsA
Study: 18240258
Drug: Anti-TNFα treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα treatment in AS
Study: 18240258
Drug: Anti-TNFα treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα treatment in RA
Study: 12442933
Drug: Cisatracurium (intubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (intubation dose 0.1 mg kg(‐1))
Study: 12442933
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg kg(‐1))
Study: 12442933
Drug: Cisatracurium (effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (effective dose 0.05 mg kg(‐1))
Study: 12442933
Drug: Cisatracurium (repeat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (repeat dose 0.02 mg kg(‐1))
Study: 10350246
Drug: High-dose tirilazad
Normalized name: TIRILAZAD
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirilazad mesylate (15 mg/kg/day)
Study: 6803633
Drug: Control exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control exercise challenges (no treatment)
Study: 22931315
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily) + Aspirin (325 mg daily)
Study: 12860867
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between atorvastatin and simvastatin
Study: 10365900
Drug: Erythromycin in
Normalized name: erythromycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin in normoglycaemia (200 mg intravenously)
Study: 10365900
Drug: Erythromycin in
Normalized name: erythromycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin in hyperglycaemia (200 mg intravenously)
Study: 10150850
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and long-term laser treatment for capsular glaucoma
Study: 2132565
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (leucovorin) supplementation given orally 4 hours after weekly low dose methotrexate administration
Study: 6110536
Drug: Active TBE-vaccination
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TBE-vaccination (purified TBE vaccine)
Study: 27518188
Drug: EVA Park
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVA Park intervention (daily language stimulation sessions for 5 weeks)
Study: 20643015
Drug: Levobupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (5 mL of levobupivacaine hydrochloride, 25 mg/10 mL) soaked Merocele packs
Study: 15777102
Drug: Oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone IR (all doses)
Study: 10959382
Drug: Losartan (Ocsaar)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (Ocsaar) 50 mg daily, increased to 100 mg if necessary
Study: 9000839
Drug: Doxazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin therapy for 3 years
Study: 7280947
Drug: Parenteral cefamandole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cefamandole
Study: 7280947
Drug: Parenteral penicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral penicillin, gentamicin and clindamycin
Study: 26078579
Drug: PUFA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA therapy (50 mL PUFA with 1:1 ratio of EHA and DHA added to daily diet)
Study: 26078579
Drug: PUFA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA therapy
Study: 23566237
Drug: Autologous fibroblast
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fibroblast treatment
Study: 19623052
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise training session for 20 mins/day using a bedside cycle ergometer
Study: 16786420
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist with low-dose hCG protocol (hCGP)
Study: 16786420
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist with no low-dose hCG protocol (NhCGP)
Study: 16786420
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (buserelin) long protocol (LP)
Study: 15475021
Drug: Intensity effect
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensity effect on insulin
Study: 11402958
Drug: iohexol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 0.6 ml/kg (G1)
Study: 11402958
Drug: iohexol 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 1.2 ml/kg (G2)
Study: 11402958
Drug: sodium and
Normalized name: Sodium and/or sodium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium and meglumine diatrizoate 58% 0.6 ml/kg (G3)
Study: 11402958
Drug: sodium and
Normalized name: Sodium and/or sodium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium and meglumine diatrizoate 58% 1.2 ml/kg (G4)
Study: 9114762
Drug: class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: class I drugs
Study: 9114762
Drug: class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: class I drugs with beta blockers
Study: 8029263
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg caffeine + 2 mg nicotine polacrilex
Study: 8029263
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg caffeine + 4 mg nicotine polacrilex
Study: 20949349
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at target MAP of 75 mmHg
Study: 20949349
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at target MAP of 60 mmHg
Study: 20949349
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion at target MAP of 90 mmHg
Study: 18187617
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NA) 1 g 60 min before, and 0.5 g 60 and 180 min after sprint 1
Study: 16303987
Drug: Medication utilization
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication utilization patterns in patients with BPD
Study: 12745514
Drug: Metacholine (MCh;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacholine (MCh; 2 and 4 mg/min) and sodium nitroprusside (SNP; 5 and 10 mg/min)
Study: 11187922
Drug: American therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: American therapy template with two post-remission intensification modules
Study: 11187922
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate injections
Study: 11187922
Drug: Age, sex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, sex, and white count >50 x 10(9)/l
Study: 8884642
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing plus application of 2% minocycline gel (S + Min)
Study: 8884642
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing plus application of 25% metronidazole gel (S + Met)
Study: 29059186
Drug: DEC and
Normalized name: insulin degludec and liraglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC and albendazole (single oral dose, repeated annually or semi-annually)
Study: 26943607
Drug: S100 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100 levels <123 pg mL-1 on PD1
Study: 25726215
Drug: Prescription at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription at home (PRES)
Study: 22994049
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pretreatment (OCP), n = 53
Study: 19923550
Drug: IV bapineuzumab
Normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bapineuzumab (0.15, 0.5, 1.0, or 2.0 mg/kg)
Study: 17525395
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of uric acid (UA)
Study: 17525395
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of uric acid (UA)
Study: 15217656
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg of midazolam IV 20 minutes preoperatively
Study: 9736008
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) of residual symptoms supplemented by lifestyle modification and well-being therapy
Study: 2571295
Drug: Beta‐adrenergic blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenergic blockers
Study: 2571295
Drug: Captopril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (100 mg) with Hydrochlorothiazide (25 mg)
Study: 2571295
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg) with Clopamide (5 mg)
Study: 180192
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon inducer (CP 20961)
Study: 180192
Drug: Drug vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug vehicle (polysorbate-80 in glycerol and saline)
Study: 180192
Drug: Oral lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lactose
Study: 27940063
Drug: Wireless pill
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless pill bottle use alone (control)
Study: 21175995
Drug: Rikkunshito (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (7.5 g day(-1) for 2 weeks)
Study: 10661479
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 4 IU/m2
Study: 10661479
Drug: placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injections
Study: 8350309
Drug: Supplementary clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary clinical instruction by general internal medicine physicians
Study: 3513642
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg mefloquine, 1.5 g sulfadoxine, 75 mg pyrimethamine (MSP)
Study: 3513642
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg quinine 8‐hourly for 3 days and 500 mg tetracycline 8‐hourly for 7 days (Q3T7)
Study: 3513642
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg quinine 8‐hourly for 7 days and 500 mg tetracycline 8‐hourly for 7 days (Q7T7)
Study: 31925727
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with diet and exercise (Control)
Study: 27523186
Drug: Bimuno-galactooligosaccharide (B-GOS)
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimuno-galactooligosaccharide (B-GOS) 5.5 g/d for 3 weeks
Study: 24062227
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 30 mg/kg TXA on induction of surgery (one shot [OS] group)
Study: 24062227
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 10 mg/kg TXA followed by continuous infusion of 2 mg/kg per hour for 20 hours (one day [OD] group)
Study: 20104197
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus lower‐molecular weight heparin treatment (LT group)
Study: 18557664
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg B(12) + 2 mg folic acid + 25 mg B(6) per day
Study: 15949922
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg sodium valproate
Study: 15949922
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg lithium
Study: 10223267
Drug: C+E (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (375 mg caffeine and 75 mg ephedrine)
Study: 31911072
Drug: Dual continuous
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual continuous theta burst stimulation (cTBS) over left inferior frontal gyrus (IFG‐L) and right inferior parietal gyrus (IPL‐R)
Study: 31911072
Drug: Single site
Normalized name: Seprafilm Single Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single site IFG‐L cTBS
Study: 21675876
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation program with exercise (nicotine replacement therapy, behavioral counseling, exercise prescription)
Study: 19131322
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive treatment
Study: 15673999
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose multivitamin/mineral supplement
Study: 11201778
Drug: Topical tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical tobramycin 0.3%
Study: 9010042
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) with tamoxifen
Study: 9010042
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) without tamoxifen
Study: 3113222
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of rt-PA
Study: 26836245
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vaginal E2 softgel capsules
Study: 24627787
Drug: Olanzapine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (both doses)
Study: 20070250
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 3 months (statin‐treated, ST n=39)
Study: 20070250
Drug: Previous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous therapy (statin‐free, SF)
Study: 10392878
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches of estradiol‐17beta
Study: 28905172
Drug: Extended-duration betrixaban
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-duration betrixaban (80 mg once daily for 35-42 days)
Study: 28905172
Drug: Standard-of-care enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care enoxaparin (40 mg once daily for 10±4 days)
Study: 25752889
Drug: THC 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC 0.75 mg
Study: 25752889
Drug: THC pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC pharmacokinetics
Study: 21333015
Drug: School-based psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based psychological intervention (cognitive-behavioural models); 11 weekly sessions and 3 booster sessions.
Study: 9385238
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (proximal realignment procedures)
Study: 7957511
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg pirsidomine
Study: 7957511
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pirsidomine
Study: 2890307
Drug: Targeted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted medication plus psychosocial intervention
Study: 23964932
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg) intravenously at weeks 0 and 2
Study: 20615906
Drug: Citrate-enriched dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-enriched dialysate (3 mEq/L)
Study: 18447215
Drug: Point sticking
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point sticking therapy (Sanleng, Ezhu, Zhi Nanxing, Bingpian applied to Qihai, Guanyuan, and Ashi points)
Study: 18447215
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Rupixiao (control group)
Study: 18447215
Drug: Point sticking
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point sticking therapy
Study: 16324916
Drug: Ephedrine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (25 mg TID) plus caffeine (200 mg TID)
Study: 16324916
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pioglitazone + Ephedrine + Caffeine)
Study: 4017422
Drug: Intravenous felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous felodipine (2.5 mg infusion over 30 minutes)
Study: 4017422
Drug: Oral felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral felodipine (27.5 mg solution)
Study: 12473552
Drug: Intravenous platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous platelet GP IIb/IIIa inhibitors
Study: 2136871
Drug: Alprazolam (4-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (4-9 mg)